Information  X 
Enter a valid email address

4d Pharma PLC (DDDD)

  Print      Mail a friend

Wednesday 12 December, 2018

4d Pharma PLC

Trading Statement

RNS Number : 1787K
4d Pharma PLC
12 December 2018
 

4D pharma plc

(the "Company" or "4D")

Trading Update

 

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, notes the recent fall in its share price, and confirms that it is not aware of any Company related matter which could be responsible for this price movement.  The Board also  confirms that all clinical study timelines continue to progress as expected.

 

For further information please contact:

4D


Duncan Peyton, Chief Executive Officer

Fay Weston, Head of Investor Relations

 

 

+ 44 (0)113 895 0130

+ 44 (0)7990 381713

Zeus Capital Limited - Nomad and Joint Broker

+44 (0) 161 831 1512

Dan Bate / Jordan Warburton

 

 


Bryan Garnier & Co. Limited - Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker


 

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform that rationally identifies novel bacteria that have a precise and evolved therapeutic effect.  All of 4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has completed a Phase I study in Irritable Bowel Syndrome and has completed dosing in a Phase I study in Paediatric Crohn's Disease.  It currently has a pipeline of 13 pre-clinical programmes, covering disease areas such as cancer, poorly controlled asthma, autoimmune and CNS disease, and plans to commence one additional clinical study in 2018 and a further three in 2019. For more information, refer to https://www.4dpharmaplc.com/.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTTBBBTMBJBTPP

a d v e r t i s e m e n t